Table 1.
Patient demographics and disease characteristics.
| Characteristics | N = 35 | % |
|---|---|---|
| Median age, years | 56.0 (40-78) | |
| Menopausal status | ||
| Premenopausea | 7 | 20.0 |
| Postmenopause | 28 | 80.0 |
| Histology of primary breast cancer | ||
| Ductal | 29 | 82.8 |
| Lobular | 4 | 11.4 |
| Mucinous | 1 | 2.9 |
| Tubular | 1 | 2.9 |
| DFIb | ||
| ≤5 y | 10 | 28.6 |
| >5 y | 16 | 45.7 |
| PgR status | ||
| Positive | 31 | 88.6 |
| Negative | 4 | 11.4 |
| Metastatic sites | ||
| Non-visceral | 25 | 71.4 |
| Bone | 20 | 57.1 |
| Bone-only | 5 | 14.3 |
| Visceral disease | 10 | 28.6 |
| Any lung | 7 | 20.0 |
| Pleural | 5 | 14.3 |
| Liver | 1 | 2.9 |
| No. of disease sites | ||
| 1 | 16 | 45.7 |
| 2 | 13 | 27.1 |
| ≥ 3 | 6 | 17.1 |
| De novo metastatic disease | 9 | 25.7 |
| Prior line of therapies for metastatic disease | ||
| 0 | 28 | 80.0 |
| 1 | 5 | 14.3 |
| 2 | 2 | 5.7 |
| Prior ET for metastatic disease | ||
| None | 30 | 85.7 |
| Yes | 5 | 14.3 |
| Prior chemotherapy for metastatic disease | ||
| None | 31 | 88.6 |
| Yes | 4 | 11.4 |
| PFS | ||
| Events | 26 | 74.3 |
| Censored | 9 | 25.7 |
ER, estrogen receptor; PgR, progesterone receptor; ET, endocrine therapy; PFS, Progression-Free Survival; DFI, Disease-free interval.
aFor premenopausal women, fulvestrant was given upon on the administration of gonadotropin-releasing hormone agonist.
bPatients with stage IV breast cancer at initial diagnosis were excluded (N = 9).